FAP and malignant pleural mesothelioma: While FAP-targeted CAR-T cells caused severe side effects such as bone marrow toxicity and cachexia [105], in a phase I clinical trial using anti-FAP CAR T-cell therapies for malignant pleural mesothelioma patients, a single infusion of anti-FAP CAR T cells was shown to be safe as long as local administration was used [106].